CytomX Therapeutics, Inc. (CTMX)
2.03
-0.02
(-0.98%)
USD |
NASDAQ |
Nov 20, 16:00
2.05
+0.02
(+0.99%)
After-Hours: 20:00
CytomX Therapeutics Shareholders Equity (Quarterly) : 284.89M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 284.89M |
| June 30, 2026 | 302.07M |
| March 31, 2026 | 319.94M |
| December 31, 2025 | 99.01M |
| September 30, 2025 | 107.39M |
| June 30, 2025 | 119.91M |
| March 31, 2025 | 25.05M |
| December 31, 2024 | -0.456M |
| September 30, 2024 | -23.45M |
| June 30, 2024 | -31.23M |
| March 31, 2024 | -31.68M |
| December 31, 2023 | -47.45M |
| September 30, 2023 | -51.24M |
| June 30, 2023 | -85.03M |
| March 31, 2023 | -86.64M |
| December 31, 2022 | -85.75M |
| September 30, 2022 | 28.47M |
| June 30, 2022 | 48.71M |
| March 31, 2022 | 68.19M |
| December 31, 2021 | -0.459M |
| September 30, 2021 | 111.67M |
| June 30, 2021 | 130.95M |
| March 31, 2021 | 146.02M |
| December 31, 2020 | 49.80M |
| Date | Value |
|---|---|
| September 30, 2020 | 48.06M |
| June 30, 2020 | 58.83M |
| March 31, 2020 | 69.77M |
| December 31, 2019 | 51.11M |
| September 30, 2019 | 82.11M |
| June 30, 2019 | 101.50M |
| March 31, 2019 | 122.57M |
| December 31, 2018 | 130.88M |
| September 30, 2018 | 157.66M |
| June 30, 2018 | 41.13M |
| March 31, 2018 | 49.65M |
| December 31, 2017 | 69.90M |
| September 30, 2017 | 45.48M |
| June 30, 2017 | 52.24M |
| March 31, 2017 | 73.79M |
| December 31, 2016 | 78.48M |
| September 30, 2016 | 89.42M |
| June 30, 2016 | 101.19M |
| March 31, 2016 | 112.79M |
| December 31, 2015 | 126.15M |
| September 30, 2015 | 53.11M |
| June 30, 2015 | 63.51M |
| March 31, 2015 | -5.998M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 33.50B |
| Arcturus Therapeutics Holdings, Inc. | 168.73M |
| Corvus Pharmaceuticals, Inc. | 208.32M |
| ACADIA Pharmaceuticals, Inc. | 1.387B |
| Alnylam Pharmaceuticals, Inc. | 3.604B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 364.68M |
| Total Liabilities (Quarterly) | 79.79M |
| Debt to Equity Ratio | 0.0154 |
| Current Ratio | 7.820 |
| Net Debt Paydown Yield | 0.08% |